Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth Levin

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Handbook of Clinical Neurology|August 10, 2020
Neuroimmunologic disorders in pregnancySeth Levin, Kathryn Rimmer, Wendy S Vargas
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 11, 2023
Vaccine response in people with multiple sclerosis treated with fumaratesMatthew A Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Psychopharmacology|September 20, 2024
Effects of zuranolone on next-day simulated driving in healthy adultsJoi Dunbar, Gaetano Morelli, Rakesh Jain, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 3, 2024
Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registryKerstin Hellwig, David Rog, Christopher McGuigan, et al.
Multiple Sclerosis and Related Disorders|October 11, 2024
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 studySamuel F Hunter, John W Lindsey, Benjamin Osborne, et al.
Journal of Psychopharmacology (Oxford, England)|October 12, 2024
Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trialJoi Dunbar, David P Walling, Howard A Hassman, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 28, 2020
Fatal COVID-19 in an MS patient on natalizumab: A case reportKathryn Rimmer, Rebecca Farber, Kiran Thakur, et al.
Neurology and Therapy|June 27, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 StudyBarry A Singer, Sibyl Wray, Mark Gudesblatt, et al.
The Journal of Clinical Psychiatry|December 28, 2023
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE StudyAndrew J Cutler, Gregory W Mattingly, Susan G Kornstein, et al.
Multiple Sclerosis and Related Disorders|September 3, 2021
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapsesSamantha E Epstein, Seth Levin, Kaho Onomichi, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Handbook of Clinical Neurology|August 10, 2020
Neuroimmunologic disorders in pregnancySeth Levin, Kathryn Rimmer, Wendy S Vargas
Multiple Sclerosis Journal - Experimental, Translational and Clinical|September 11, 2023
Vaccine response in people with multiple sclerosis treated with fumaratesMatthew A Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Psychopharmacology|September 20, 2024
Effects of zuranolone on next-day simulated driving in healthy adultsJoi Dunbar, Gaetano Morelli, Rakesh Jain, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 3, 2024
Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registryKerstin Hellwig, David Rog, Christopher McGuigan, et al.
Multiple Sclerosis and Related Disorders|October 11, 2024
Safety, tolerability, and efficacy of diroximel fumarate in a cohort of Black patients with multiple sclerosis from the phase 3 EVOLVE-MS-1 studySamuel F Hunter, John W Lindsey, Benjamin Osborne, et al.
Journal of Psychopharmacology (Oxford, England)|October 12, 2024
Cognitive effects, pharmacokinetics, and safety of zuranolone administered alone or with alprazolam or ethanol in healthy adults in a phase 1 trialJoi Dunbar, David P Walling, Howard A Hassman, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|August 28, 2020
Fatal COVID-19 in an MS patient on natalizumab: A case reportKathryn Rimmer, Rebecca Farber, Kiran Thakur, et al.
Neurology and Therapy|June 27, 2024
Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing-Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 StudyBarry A Singer, Sibyl Wray, Mark Gudesblatt, et al.
The Journal of Clinical Psychiatry|December 28, 2023
Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE StudyAndrew J Cutler, Gregory W Mattingly, Susan G Kornstein, et al.
Multiple Sclerosis and Related Disorders|September 3, 2021
Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapsesSamantha E Epstein, Seth Levin, Kaho Onomichi, et al.
Pageof 2